Hypereosinophilic Syndrome in the Tyrosine Kinase Inhibitor Era
نویسندگان
چکیده
منابع مشابه
Hypereosinophilic syndrome in the tyrosine kinase inhibitor era.
Hypereosinophilic syndrome (HES) is a rare disorder characterized by persistent hypereosinophilia (HE) and organ dysfunction that occurs as a result of high levels of tissue eosinophil infiltration and/or extensive deposition of eosinophil-derived proteins. Because it is often difficult to make the differential diagnosis of HES despite conducting a careful evaluation, identifying particular pat...
متن کاملReversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor.
We report a case of idiopathic hypereosinophilic syndrome in a young man, who showed symptoms and electrocardiographic findings mimicking an acute coronary syndrome. Two-dimensional echocardiography, together with laboratory data, allowed us to make the diagnosis and to start a treatment with imatinib mesylate, a 2-phenylamonopyrimidine-based tyrosine kinase inhibitor, which reversed the cardia...
متن کاملIdiopathic Hypereosinophilic Syndrome
Idiopathic hypereosinophilic syndrome is a multisystem disease with peripheral blood eosinophilia of at least 6 months duration, multiple organ system involvement, and no evidence for other known causes of eosinophilia. It is characteristically a disease of middle-aged men, often has a poor prognosis and is seldom found during childhood. Heart dicsease, characterized by endomyocardial fibrosis ...
متن کاملChanges in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease characterized by a reciprocal translocation between long arms of chromosomes 9 and 22 t(9;22) that generates the BCR-ABL fusion gene. If left untreated, newly diagnosed chronic phase CML patients finally progress to accelerated and blastic phase. After the introduction of tyrosine kinase inhibitors (TKIs), treatment strategie...
متن کاملTyrosine kinase inhibitor-induced macrocytosis.
BACKGROUND The tyrosine kinase inhibitors (TKI) sunitinib and imatinib were shown to induce macrocytosis in patients with renal cell cancer (RCC) and gastrointestinal stromal tumors (GIST), presumably through inhibition of the c-KIT dependent signaling pathway of erythroid progenitor cells of the bone marrow. PATIENTS AND METHODS Hematology charts of patients with RCC, breast cancer (BC), GIS...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Internal Medicine
سال: 2015
ISSN: 0918-2918,1349-7235
DOI: 10.2169/internalmedicine.54.3258